{"name":"Neurotech Pharmaceuticals","slug":"neurotech-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFExZC0tNU1iT09JQWdGRXZVTWszUkpFbGJfNDJ6RG1xelFmdF95Q1g0U0tkR1pqdkNXVHdTYlFKS2VGV3NVWlRHaVpMa3VIaXUzZGN4Wl9DMWR2Z3cyN09mVGREMmxjU0NZYlAxajE4WlJ1WFlMMEhKWWRyRmtUWm51RVVsWXNaVld3bkt2TzBDaUZCTjF6cElxZTJNVFlTTkRwUkY4MUpQUQ?oc=5","date":"2026-03-24","type":"pipeline","source":"Fast Company","summary":"The most innovative medicine, therapeutics, and pharmaceutical companies of 2026 - Fast Company","headline":"The most innovative medicine, therapeutics, and pharmaceutical companies of 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBKQjVRa3Fjay05WEdjelFUYkNVdVQ5VFFPYk42eGRvLXpTOVJYdHJaTjY4RjE3VHlmOWM0SDV1QmZKNEJXTmg0YVd2eEptbllhaklWQy1vRWdwNC1aUmptb1BfdGZLUQ?oc=5","date":"2026-01-05","type":"regulatory","source":"Fierce Pharma","summary":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products - Fierce Pharma","headline":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5KTk9lRVVPM3FzV0ZGbXBwMDg3NUJUdHVJamdmUlg4MFZ2OUFFNk5mVXRBT3pJbVNBaVlueDhBU25iMjRHWXdITzhCMmh5aDZuWVFoeDgtYXVSOG9kRXA1aWNSV1Z6SW5KRnhwY3ZQNWhkVWw1Zktn?oc=5","date":"2025-09-30","type":"deal","source":"BeInCrypto","summary":"4 Medical Firms Rebranded as Crypto to Buy These Tokens - BeInCrypto","headline":"4 Medical Firms Rebranded as Crypto to Buy These Tokens","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOV3NKX19DdDZteTZ2djUtUTRmVUR4bjBuQ0ltTDZ5U1RUQmVKUGZrMVcxdGJvUm5pYV9uT0VCbk9DcFFnbG1VdTdmalBsUTNmZ2xqRlgzVjQ4NVhNLUdCTEp1anEtZ015MU9DNmQ3OFRUQmRaZDBFenkyY2tGS1l1V1lWbTlteXRmUEl6Y3B0aGZWaEtJMHJadnhWTVlNRFk1UjBDT1Ric3I?oc=5","date":"2025-08-27","type":"patent","source":"pharmaphorum","summary":"Neurotech patents in Europe: Methods, medical devices, and the EPC exclusion - pharmaphorum","headline":"Neurotech patents in Europe: Methods, medical devices, and the EPC exclusion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPZlNTTUZ0c29NWFloOUVxV2U2ZldqdVVBTVBnUmFMM2NJaXlSOXpXZzdEWUNaV29JbFJLdm9WVHhaazBqQVlxdjVGSXdJaTQtOHFXa3NJai1JNzlTYXE5Z3NEYXdyaXBfV1o1dWtfNG1FMXI5VTlMVTE5Zzk2ellkMmhBTEtMNW5rWWJiOFluT3ZEQVNnM1Yw?oc=5","date":"2025-07-04","type":"pipeline","source":"PharmTech.com","summary":"Advanced Solutions for Sustained Delivery of Ocular Therapies - PharmTech.com","headline":"Advanced Solutions for Sustained Delivery of Ocular Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9PU3dqMzhLWERuSGZXa0xGZ09pYnp4TWx6VGhiV2xZeXVjX094eDlzQzJKVFdKY29WN2o5Z0dPSXlfdEM3S1N2VkxXVEpaZjlsbnBQUjJwZnhOWmJjVWtSMERvSGYySGM?oc=5","date":"2025-05-29","type":"pipeline","source":"Anton Health","summary":"Limited Distribution Updates - Anton Health","headline":"Limited Distribution Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNTU9TR25VUEhRMEFrbl9yVU0wNktHYWhhQ2JoWkxwZEY5Tk5WcEVlcUlmUGdaMHJjbjU2b29OVTQ1OHdqeWpGVmljQWxWQ1FIVFB4dy1OX3VITWlyUTNOU2JwTEhxbTBzMmp4WGt6R2RhSk1ERzhhcVFuWHp2T05vMHdfbHUyMUlMWGJnZ3ltVEJucFl0dTI1R3dXZVFHUmNHMURzZDIwNnhWV0NrN2g0bnJuY3RoVFZ4UEtGOHVjSW1aUDkxN0E?oc=5","date":"2025-05-09","type":"pipeline","source":"Healio","summary":"VIDEO: Neurotech prepares to launch Encelto for macular telangiectasia type 2 - Healio","headline":"VIDEO: Neurotech prepares to launch Encelto for macular telangiectasia type 2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQb2c1N25DdE5Od2pDTC1MYUtmNFVwdFVnQ3FLZWVlZkdXbEJ2dGNQUUxNNTlLZWtjeEUxNzBMOE5lNFJqY3NqOF9qc3dfNE1zallENmtIZk5UamdOX3ZOdzhRRXpfR2JkOC1DNlBUR2k4Z1pCY0lCdmNOSkswLTBESkNhTFVCOVQ2VEFWUjg5LXF1V0xxbFViRmpKSDUwZw?oc=5","date":"2025-04-25","type":"pipeline","source":"Fierce Biotech","summary":"Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders - Fierce Biotech","headline":"Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQcHVyTjlCWkwwOHNRZXY3RUZ6QmR0Y2NvRGVIY2YxSVZrcGJta2EzUTh2ekdRYy1sS3dkOU9HcUlpR1AzZnltVnE3OGdYV2VqODVxNWR6S255YWdlSVkzQzNkb1hJX010MUZqLXBMMFFGSFZXM0pSNzhmSXQtNmVlTFg0Zk1SZjhPQTUwZEdfaUVkN3BwYjI5YjhOUUp4ZFZZNHBjQ2VPZHRDM09yc3Z3akF5THBjWEJrSkx5NlJRc3Q0cmdnTmJIVTZZT1g?oc=5","date":"2025-04-01","type":"pipeline","source":"PR Newswire","summary":"Orsini Selected as the Exclusive Specialty Pharmacy for Cell Therapy ENCELTO™ - PR Newswire","headline":"Orsini Selected as the Exclusive Specialty Pharmacy for Cell Therapy ENCELTO™","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE42TGpGM01qZkNGbktfR2NXWTYxLTNDSzJxSGFnZC1vWnhpVzBaNlF4NUJsbGZrZksyLXRwNXA3VU9WbUVxSnYwZWM5amotRHBCZC1N?oc=5","date":"2025-03-06","type":"regulatory","source":"FirstWord Pharma","summary":"FDA green lights first drug for rare progressive retinal vascular disease - FirstWord Pharma","headline":"FDA green lights first drug for rare progressive retinal vascular disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOTkd6NTdSajFaRU8xeGxId2IzeVFqcTQtY0ZjemlvRms5RjhadDNRdDBGWTJvWGFQV0pPeHoySFJJTGx5TjZkdlJRS2VNVnJ4OWRqWnhmcTQ2d3NXaWdFdlhpQXNXazh3SUdfZUsweFV4c1RrY1ZYVDFCVzJRaVhuR1hqNWwyMFNxSnBSSEZEaGZOam9raUdtQzhVd2RMbWNKcENBVzF4NXNKT2JmbFVEaDZhbw?oc=5","date":"2025-03-06","type":"regulatory","source":"Pharmacy Times","summary":"FDA Approves Revakinagene Taroretcel, Marking First Treatment for MacTel Type 2 - Pharmacy Times","headline":"FDA Approves Revakinagene Taroretcel, Marking First Treatment for MacTel Type 2","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOelRkR08wUnJNRjhNakVBTnpYeEVGTzZpQktIV1RxUTVtMFlWbm9vWEJxVFozbkpZZmpUeTRmT01mMzBuV3FFUmVfWWdkOGQxbGhZMk9IWkpQanNTdXdRbE5ENXJNaGs4VmR5Z29fVkYtRXl2UEZXV3dWUGNRWDA5QjlpQnF3ZlJnSWRqZUQ1Z3h6czloY0xqS19vdmE5RVZpRm5XNTVEbHlwV1VSdDJxWDNwVXZUOHlvS0hr?oc=5","date":"2024-06-24","type":"pipeline","source":"Eyes On Eyecare","summary":"Neurotech Pharma earns BLA priority review for MacTel cell therapy - Eyes On Eyecare","headline":"Neurotech Pharma earns BLA priority review for MacTel cell therapy","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}